Salarius Pharmaceuticals Q2 EPS $(1.43) Misses $(1.30) Estimate
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals reported Q2 losses of $(1.43) per share, missing the analyst consensus estimate of $(1.30) by 10 percent. However, this is a 36.44 percent improvement over losses of $(2.25) per share from the same period last year.
August 10, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Salarius Pharmaceuticals' Q2 earnings per share of $(1.43) missed the estimate of $(1.30), but improved 36.44% YoY.
Salarius Pharmaceuticals reported a larger than expected loss for Q2, which could negatively impact investor sentiment and drive the stock price down in the short term. However, the YoY improvement might mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100